A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies | Zendy

Katharine A. Collier | Zendy; Hugo E. Valencia | Zendy; Herbert B. Newton | Zendy; Erinn M. Hade | Zendy; Douglas W. Sborov | Zendy; Robert Cavaliere | Zendy; Ming Poi | Zendy; Mitch A. Phelps | Zendy; Sophia Liva | Zendy; Christopher C. Coss | Zendy; Jiang Wang | Zendy; Soun Khountham | Zendy; Paul Monk | Zendy; Charles L. Shapiro | Zendy; Richard Piekarz | Zendy; Craig C. Hofmeister | Zendy; D. Bradley Welling | Zendy; Amir Mortazavi | Zendy

Open Access

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Author(s) -

Katharine A. Collier,

Hugo E. Valencia,

Herbert B. Newton,

Erinn M. Hade,

Douglas W. Sborov,

Robert Cavaliere,

Ming Poi,

Mitch A. Phelps,

Sophia Liva,

Christopher C. Coss,

Jiang Wang,

Soun Khountham,

Paul Monk,

Charles L. Shapiro,

Richard Piekarz,

Craig C. Hofmeister,

D. Bradley Welling,

Amir Mortazavi

Publication year - 2021

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-020-04229-3

Subject(s) - medicine , neurofibromatosis type 2 , tolerability , nausea , response evaluation criteria in solid tumors , adverse effect , oncology , cancer , gastroenterology , phases of clinical research , surgery , clinical trial , neurofibromatosis , pathology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research